Market Place
News Type
Pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme. 
X
Details:
An experimental coronavirus vaccine developed by Translate Bio and Sanofi SA induced immune response in non-human studies, with trials in humans expected to start in November.
Lead Product(s): mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
DDF Summit 2022 US
Not Confirmed
Contact SupplierDetails:
This non-exclusive licence agreement, will enable MPP to support the identification of suitable partners for the development and commercialisation of mdc-STM, an injectable formulation of ivermectin with a three-month action-duration.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: mdc-STM
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: The Medicines Patent Pool
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 13, 2022
Details:
The agreement with GTP relates to the development of Covid-19 Anti-CD40.COV2 vaccine, from development of the cell line to production of a clinical batch to be tested in a clinical trial. LinKinVax’s technology is based on a monoclonal antibody that targets dentritic cells.
Lead Product(s): Covid-19 Anti-CD40.COV2 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Covid-19 Anti-CD40.COV2
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: GTP Bioways
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 15, 2022
Details:
The funding for Antabio will allow to continue the development of ANT3310 towards clinical studies and reach crucial milestones such as the clinical demonstration of its safety and tolerability in humans.
Lead Product(s): ANT3310,Meropenem
Therapeutic Area: Infections and Infectious Diseases Product Name: ANT3310
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Funding January 06, 2022
Details:
The investigational product mdc-STM aims at reducing the transmission of the parasite responsible for Malaria, thanks to a killing effect on the vector mosquitoes when they bite treated people.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: mdc-STM
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2021
Details:
Mutabilis’ new intravenous drug, EBL-1463, is a novel class of non-beta-lactam inhibitor of penicillin binding proteins (PBPs) called dabocins. Mutabilis’ new drug aims to treat deadly ‘nightmare bacteria’ infections safely and effectively.
Lead Product(s): EBL-1463
Therapeutic Area: Infections and Infectious Diseases Product Name: EBL-1463
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: CARB-X
Deal Size: $5.8 million Upfront Cash: Undisclosed
Deal Type: Funding February 03, 2021
Details:
The French State's funding, totaling €5.8 million for the entire consortium and including €5.2 million for OSE Immunotherapeutics, will in particular support the CoVepiT 1 study.
Lead Product(s): CoVepiT
Therapeutic Area: Infections and Infectious Diseases Product Name: CoVepiT
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $6.3 million Upfront Cash: Undisclosed
Deal Type: Funding December 18, 2020
Details:
The human ex vivo clinical study, named CoVepiT 1, was conducted in 120 convalescent COVID-19 subjects versus unexposed subjects. Primary Objective Achieved in Human Ex Vivo Study. .
Lead Product(s): CoVepiT
Therapeutic Area: Infections and Infectious Diseases Product Name: CoVepiT
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
Valneva’s vaccine candidate, VLA2001, is based on a proven approach and will leverage the company’s existing manufacturing platform being used for its US FDA and EMA approved Japanese Encephalitis (JE) vaccine.
Lead Product(s): VLA2001,CpG 1018
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: U.K. Government
Deal Size: $1,611.0 million Upfront Cash: Undisclosed
Deal Type: Partnership September 14, 2020
Details:
Data support potential as novel and differentiated COVID-19 vaccine designed against multiple SARS-CoV-2 targets with technology known to induce memory T lymphocytes.
Lead Product(s): CoVepiT
Therapeutic Area: Infections and Infectious Diseases Product Name: CoVepiT
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020
